Preferred Label : Anti-HER2 Antibody-drug Conjugate FDA022-BB05;
NCIt synonyms : Anti-HER2 ADC FDA022-BB05; ADC FDA022-BB05; Trastuzumab/DXd ADC FDA022-BB05;
NCIt definition : An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody directed
against the tumor-associated antigen (TAA) human epidermal growth factor receptor
2 (EGFR2; HER2; ErbB2), conjugated, via a valine-alanine (Val-Ala)-based cathepsin
B-cleavable linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan derivative
DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration,
anti-HER2 ADC FDA022-BB05 targets and binds to HER2 expressed on tumor cells. Upon
binding, internalization, and linker cleavage, DXd is released. DXd inhibits DNA topoisomerase
I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest
and tumor cell apoptosis. This inhibits the proliferation of HER2-expressing tumor
cells. FDA022-BB05 is also able to induce a bystander effect on neighboring cells
in the tumor environment. This further inhibits the proliferation of tumor cells.
HER2, a receptor tyrosine kinase that is mutated or overexpressed in many tumor cell
types, plays an important role in tumor cell proliferation and tumor vascularization.;
Molecule name : FDA022 BB05; FDA022-BB05;
Origin ID : C216085;
concept_is_in_subset
- has_target
